EMA confirms suspension of sickle cell disease medicine Oxbryta

View source ↗

Summary

EMA has suspended Oxbryta (voxelotor) for sickle cell disease after trials showed a higher rate of death and disease complications, so the benefit‑risk balance …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Higher rate of death and disease complications in recent trials means benefit-risk balance no longer favourable